Artisan phakic iris claw intraocular lens for high primary and secondary hyperopia.
OBJECTIVE
To evaluate the efficacy, predictability, and safety of the Artisan iris claw phakic intraocular lens for the correction of high primary and secondary hyperopia.


METHODS
Fifty-seven eyes were divided into two groups: 29 eyes had primary hyperopia (mean refraction 6.06 +/- 1.26 D, and 28 eyes had secondary hyperopia, (mean refraction 5.88 +/- 1.88 D) induced or residual following a previous corneal refractive procedure. Consecutive implantation of the Artisan iris claw phakic intraocular lens was performed. Main outcome measures recorded were BSCVA, UCVA, refraction, and astigmatic change, intraocular inflammation, and endothelial cell loss.


RESULTS
Primary hyperopic group: Preoperatively, mean UCVA was 0.4 +/- 0.7 and mean BSCVA was 0.2 +/- 0.6. After implantation, mean UCVA was 0.3 +/- 0.6 and BSCVA was 0.1 +/- 0.6. Mean cycloplegic residual spherical refractive error after surgery was 0.10 +/- 0.57 D (range -1 to +2 D). Mean surgically induced astigmatism was 1.48 +/- 0.89 D. Safety index was 1.11. Efficacy index was 0.83. Secondary hyperopic group: Preoperatively, mean UCVA was 0.5 +/- 0.7 and mean BSCVA was 0.2 +/- 0.6. Postoperatively, mean UCVA was 0.4 +/- 0.7 and mean BSCVA was 0.2 +/- 0.6. Mean cycloplegic residual spherical refractive error was 0.55 +/- 1.49 D. Mean surgically induced astigmatism was 1.85 +/- 1.19 D. Safety index was 1.05. Efficacy index was 0.7. Postoperative iridocyclitis was observed in one eye (3.4%) in the primary group and in three eyes (10.7%) in the secondary group. Overall corneal endothelial cell loss at 1 year of follow-up was 9.4%.


CONCLUSIONS
The Artisan iris claw phakic intraocular lens was reasonably safe and predictable for correcting high hyperopia.
Alió
Jorge L
JL
Instituto Oftalmológico de Alicante (Department of Refractive Surgery), Miguel Hernández University, Medical School, Alicante, Spain. jlalio@oftalio.com
Mulet
M Emilia
ME
Shalaby
Ahmad M M
AM
D000328:Adult; D001251:Astigmatism / Q000209:etiology / Q000503:physiopathology; D002452:Cell Count; D004728:Endothelium, Corneal / Q000473:pathology; D005548:Foreign-Body Migration / Q000503:physiopathology; D006801:Humans; D006956:Hyperopia / Q000209:etiology* / Q000601:surgery*; D007429:Intraocular Pressure; D015863:Iridocyclitis / Q000209:etiology / Q000473:pathology; D019654:Lens Implantation, Intraocular / Q000009:adverse effects / Q000295:instrumentation; D007910:Lenses, Intraocular; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects*; D011680:Pupil; D012029:Refraction, Ocular; D054140:Refractive Surgical Procedures; D012449:Safety; D012542:Scattering, Radiation; D016896:Treatment Outcome; D014792:Visual Acuity